Table 2 Comparison between PD-dn and PD-dt.

From: Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson’s Disease

 

PD-dn

PD-dt

P

n

16

37

 

Gender (F/M)

7/9

10/27

0.337

Age (years)

65.6 ± 10.8

71.4 ± 8.4

0.041 a

UPDRS Part II (score)

6.9 ± 4.7b

7.5 ± 2.6b

0.606d

UPDRS Part III (score)

9.9 ± 5.9d

15.6 ± 5.3

0.002 a

H&Y scale (stage)

1.2 ± 0.4

1.8 ± 0.5

<0.001 a

LED (mg/day)

 

459.4 ± 247.4

 

Drugs

   

l -DOPA (n)

 

27e

 

DA agonists (n)

 

27f

 

pramipexole (n)

 

19

 

ropinirole (n)

 

4

 

rotigotine (n)

 

4

 

Rasagiline (n)

 

19

 
  1. Data are means ± SD unless otherwise indicated.
  2. Notes: a = by Student’s t test; b = data missing for 1 PD-dn and 11 PD-dt; c = data missing for 1 PD-dn patient; d = by Mann–Whitney U test; e = 8 taking l-DOPA alone, and 19 taking l-DOPA+ DA agents; f = 10 taking DA agonists alone (4) or with rasagiline (6), and 17 taking DA agonists+ l-DOPA, without (6) or with rasagiline (11).
Back to article page